Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact

September 2022 – – Entera Bio hosted a key opinion leader (KOL) webinar on the company’s lead asset EB613, and its potential impact on the osteoporosis market. The webinar featured presentations from KOLs John P. Bilezikian, MD, PhD, from Columbia University, Felicia Cosman, MD, also from Columbia University, and Bart L. Clarke, MD, from Mayo Clinic. The event provided insight into the current treatment landscape and unmet medical need for post-menopausal women with osteoporosis. The discussion focused on Entera Bio’s development of EB613, a proprietary formulation of PTH (1-34, teriparatide) as the first potential orally administered osteoanabolic treatment. Entera leadership will review their Phase 2 EB613 data, which will be followed by an overview of the Company’s proposed registrational Phase 3 plan submitted to FDA.

Watch Event

READ MORE

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Thank You

Message Sent!

We will get back to you soon